TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01761513
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks
Study: NCT01761513
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks
Study: NCT01761513
Drug: YH4808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks
Study: NCT03581175
Drug: Bowel cleansing regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01903265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Study: NCT01381367
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline, 0.5ml given subcutaneously
Study: NCT02173405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of placebo with investigational drug OnabotulinumtoxinA
Study: NCT02879513
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02879513
Drug: 5-fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 6 weeks
Study: NCT01774773
Drug: Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Study: NCT01774773
Drug: Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Study: NCT01774773
Drug: Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively.
Study: NCT01126190
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
Study: NCT04184505
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)
Study: NCT00829374
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally three times daily
Study: NCT01046682
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
Study: NCT03320187
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
Study: NCT03100318
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dosing for 14 weeks
Study: NCT03245346
Drug: GEA
Normalized name: Geangin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
Study: NCT03245346
Drug: PCEA
Normalized name: Patient-Controlled Epidural Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
Study: NCT01001351
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically during surgery.
Study: NCT01001351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically during surgery
Study: NCT02852967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching belumosudil
Study: NCT05940506
Drug: KX-826-2.5 mg (0.25%)/60 mL BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
Study: NCT05940506
Drug: KX-826-5 mg (5%)/60 mL QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
Study: NCT05940506
Drug: KX-826-5 mg (5%)/60 mL BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
Study: NCT01273402
Drug: TF2/IMP288
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
Study: NCT04286152
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
Study: NCT04015245
Drug: Stronger Neo-Minophagen C
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection after TACE
Study: NCT03460652
Drug: KP415 oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral dose
Study: NCT01030120
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02631954
Drug: Vfend®(Voriconazole) IV 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vfend®(Voriconazole) IV 200mg to administered intravenously once
Study: NCT01747915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
Study: NCT00737724
Drug: Deferred RV and antiMTB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
Study: NCT00670566
Drug: irbesartan/hydrochlorothiazide
Normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
Study: NCT04327232
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mineralocorticoid Receptor Antagonists
Study: NCT04327232
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00002631
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00803738
Drug: Terazol Vaginal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
Study: NCT00650052
Drug: Zonegran® Capsules 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fasting
Study: NCT00486356
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002631
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03036852
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
Study: NCT00363571
Drug: GTN, Diamox
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00129285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 400 mg/day
Study: NCT04145076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two oral doses of placebo.
Study: NCT02409433
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
Study: NCT02065492
Drug: Standard Chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
Study: NCT03068897
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen
Study: NCT01998061
Drug: EGFR tyrosine kinase inhibitor
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A
Study: NCT01998061
Drug: EGFR tyrosine kinase inhibitor with chemotherapy
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm B
Study: NCT02782845
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
Study: NCT02782845
Drug: Immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
Study: NCT04648917
Drug: Caffeic acid
Normalized name: CAFFEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
Study: NCT03657836
Drug: Standard antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
Study: NCT03415503
Drug: Medox® Anthocyanin capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were orally administered Medox® capsules daily for 12 weeks.
Study: NCT00484341
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
Study: NCT02063685
Drug: Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: not maintenance therapy and followed-up with MRD monitoring.
Study: NCT02063685
Drug: Standard Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
Study: NCT01725802
Drug: Levodopa/carbidopa solution for SC administration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01094834
Drug: DWP05195
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, oral administration, multiple administration
Study: NCT00777959
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
Study: NCT00938613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray, one spray per nostril at time 0
Study: NCT02457247
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
Study: NCT02457247
Drug: Adcal-D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
Study: NCT02457247
Drug: Kalcipos-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
Study: NCT01239173
Drug: AVLOCARDYL
Normalized name: Avlocardyl Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Study: NCT01239173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
Study: NCT01420510
Drug: Placebo vaginal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a placebo vaginal gel
Study: NCT04464551
Drug: [14C]D-0316 suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
Study: NCT04324892
Drug: Treat to target
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patient will received protocolized treatment with an aim to achieve SDAI remission
Study: NCT04153084
Drug: PEG-3350 with electrolytes
Normalized name: PEG-3350 with Electrolytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
Study: NCT03931226
Drug: Drug consumption
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
Study: NCT00811720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: as-needed use, tablets, orally, 6 months
Study: NCT00889707
Drug: PRX302
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Study: NCT00889707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
Study: NCT02590536
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03046836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT01293136
Drug: Intravenous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whatever opioids prescribed
Study: NCT02156024
Drug: Gastrodia and Uncaria Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
Study: NCT02067143
Drug: Cycle 1 Induction
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 2 Induction / Early consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 3 Early consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 4 Consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 5 Consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 6 Consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 7 Consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02067143
Drug: Cycle 8 Reinduction
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03123770
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: a new kind of doxorubicin
Study: NCT03123770
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: traditional chemotherapy drug
Study: NCT02264743
Drug: Femoston Conti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
Study: NCT02264743
Drug: EVOREL® CONTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
Study: NCT02390492
Drug: Period 1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
Study: NCT03570346
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Study: NCT03570346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Study: NCT03711487
Drug: Foeniculum Vulgare Seed Ironing
Normalized name: FOENICULUM VULGARE (FENNEL) SEED EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
Study: NCT04227327
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2,5 mg daily or Anastrozole 1 mg daily
Study: NCT04240106
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study: NCT01520467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet /day administered orally for 18 months.
Study: NCT00803868
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching study drug up to 1mg po bid
Study: NCT04400682
Drug: AVIGAN 200 MG Film Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Study: NCT04268069
Drug: PL9643 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Study: NCT04268069
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Study: NCT04410159
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargle
Study: NCT01361217
Drug: Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water.
Study: NCT03204877
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capsules